Breaking News Instant updates and real-time market news.

NVS

Novartis

$93.58

-0.715 (-0.76%)

05:09
07/22/19
07/22
05:09
07/22/19
05:09

Sandoz enrolls first patient in ROSALIA integrated Phase I/III clinical study

Sandoz, a Novartis division, announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar denosumab. The study aims to confirm that the biosimilar matches the reference medicine in terms of pharmacokinetics, efficacy, safety, and immunogenicity in patients with postmenopausal osteoporosis.

  • 22

    Jul

  • 23

    Jul

  • 25

    Sep

NVS Novartis
$93.58

-0.715 (-0.76%)

06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/18/19
WELS
07/18/19
NO CHANGE
WELS
Novartis' Sandoz trends a negative for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris said that while Novartis' (NVS) Sandoz Q2 results were better than expected, they were mainly driven by ex-U.S. performance, and the analyst believes this could have "negative implications for other companies with significant U.S. commodity generics, such as Teva (TEVA) and Mylan (MYL) though perhaps moreso for Mylan." Maris noted that on the conference call, Novartis stated, "If you take out one-time, certain one-time effects, you would see that in the U.S. the base business continues to have declines in the mid-teens consistent with what we've seen in past quarters, so we haven't seen yet a stabilization in the core GX business in the U.S." The analyst concluded that the commentary is consistent with his "continued caution on generics."

TODAY'S FREE FLY STORIES

PCG

PG&E

$11.64

-0.565 (-4.63%)

06:03
09/23/19
09/23
06:03
09/23/19
06:03
Hot Stocks
PG&E executes agreement resolving claims relating to 2017, 2018 wildfires »

PG&E Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Oct

  • 10

    Nov

  • 10

    Nov

  • 07

    Jan

ELAN

Elanco

$27.48

0.325 (1.20%)

06:03
09/23/19
09/23
06:03
09/23/19
06:03
Initiation
Elanco initiated  »

Elanco initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CHWY

Chewy

$26.44

-1.06 (-3.85%)

06:00
09/23/19
09/23
06:00
09/23/19
06:00
Upgrade
Chewy rating change  »

Nomura Instinet upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXAS

Exact Sciences

$104.03

0.66 (0.64%)

05:56
09/23/19
09/23
05:56
09/23/19
05:56
Hot Stocks
Exact Sciences says Cologuard gains FDA approval for use in ages 45-49 »

Exact Sciences announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

APTV

Aptiv

$87.10

-2.41 (-2.69%)

, HYMTF

Hyundai Motor

$0.00

(0.00%)

05:53
09/23/19
09/23
05:53
09/23/19
05:53
Hot Stocks
Aptiv, Hyundai Motor to form autonomous driving JV »

Aptiv (APTV) and Hyundai…

APTV

Aptiv

$87.10

-2.41 (-2.69%)

HYMTF

Hyundai Motor

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RKDA

Arcadia Biosciences

$5.29

-0.23 (-4.17%)

05:47
09/23/19
09/23
05:47
09/23/19
05:47
Hot Stocks
Arcadia Biosciences granted U.S. patent for reduced gluten GoodWheat »

Arcadia Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$4.76

-0.1 (-2.06%)

05:38
09/23/19
09/23
05:38
09/23/19
05:38
Hot Stocks
Clovis acquires rights to FAP »

Clovis Oncology has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

TRV

Travelers

$146.32

-0.69 (-0.47%)

05:37
09/23/19
09/23
05:37
09/23/19
05:37
Hot Stocks
Travelers receives approval to transfer European business to Dublin »

Travelers announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

DEA

Easterly Government Properties

$20.96

0.02 (0.10%)

05:37
09/23/19
09/23
05:37
09/23/19
05:37
Initiation
Easterly Government Properties initiated  »

Easterly Government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

TEL

TE Connectivity

$93.21

-1.21 (-1.28%)

05:34
09/23/19
09/23
05:34
09/23/19
05:34
Downgrade
TE Connectivity rating change  »

TE Connectivity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWDBY

Swedbank

$0.00

(0.00%)

05:33
09/23/19
09/23
05:33
09/23/19
05:33
Upgrade
Swedbank rating change  »

Swedbank upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLOY

EssilorLuxottica

$0.00

(0.00%)

05:32
09/23/19
09/23
05:32
09/23/19
05:32
Upgrade
EssilorLuxottica rating change  »

EssilorLuxottica upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWY

Chewy

$26.44

-1.06 (-3.85%)

05:30
09/23/19
09/23
05:30
09/23/19
05:30
Upgrade
Chewy rating change  »

Chewy upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEXAY

Atos

$0.00

(0.00%)

05:29
09/23/19
09/23
05:29
09/23/19
05:29
Upgrade
Atos rating change  »

Atos upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$238.80

3.2 (1.36%)

05:28
09/23/19
09/23
05:28
09/23/19
05:28
Hot Stocks
Biogen says Plegridy, Avonex receive 'positive opinion' from CHMP »

Biogen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ACN

Accenture

$192.99

-1.78 (-0.91%)

05:28
09/23/19
09/23
05:28
09/23/19
05:28
Initiation
Accenture initiated  »

Accenture initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Oct

TELDF

Telefonica Deutschland

$0.00

(0.00%)

05:27
09/23/19
09/23
05:27
09/23/19
05:27
Upgrade
Telefonica Deutschland rating change  »

Telefonica Deutschland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGY

VAALCO Energy

$2.08

0.06 (2.97%)

05:26
09/23/19
09/23
05:26
09/23/19
05:26
Initiation
VAALCO Energy initiated  »

VAALCO Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$11.64

-0.565 (-4.63%)

05:25
09/23/19
09/23
05:25
09/23/19
05:25
Hot Stocks
PG&E expects to turn off power late Monday in nine CA counties due to fire risk »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Oct

  • 10

    Nov

  • 10

    Nov

  • 07

    Jan

AIBRF

AIB Group

$0.00

(0.00%)

05:25
09/23/19
09/23
05:25
09/23/19
05:25
Upgrade
AIB Group rating change  »

AIB Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAOFY

Tatneft

$0.00

(0.00%)

05:22
09/23/19
09/23
05:22
09/23/19
05:22
Downgrade
Tatneft rating change  »

Tatneft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESYJY

easyJet

$0.00

(0.00%)

05:21
09/23/19
09/23
05:21
09/23/19
05:21
Upgrade
easyJet rating change  »

easyJet upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLOWY

Vallourec

$0.00

(0.00%)

05:20
09/23/19
09/23
05:20
09/23/19
05:20
Downgrade
Vallourec rating change  »

Vallourec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELNY

Telenor

$0.00

(0.00%)

05:15
09/23/19
09/23
05:15
09/23/19
05:15
Downgrade
Telenor rating change  »

Telenor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANNSF

Aena

$0.00

(0.00%)

05:14
09/23/19
09/23
05:14
09/23/19
05:14
Downgrade
Aena rating change  »

Aena downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.